Recently, there are rumors of a five-way merger between biotechnology companies - Xenova, Oxford Glycosciences, KS Biomedix, Antisoma and, possibly, British Biotech, to create a leader in anticancer therapy - dubbed UK Oncology plc. This article considers the roles of these particular companies and the benefits and pitfalls that could occur to a merged entity.